Quantcast

Latest UCB Stories

2009-10-26 10:00:00

SAN DIEGO, Oct. 26 /PRNewswire/ -- According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study. These...

2009-10-26 10:00:00

SAN DIEGO, Oct. 26 /PRNewswire/ -- New data from an open-label extension study evaluating the long-term safety and efficacy of CIMZIA® (certolizumab pegol) in moderate to severe Crohn's disease patients demonstrate that 82 percent of patients actively treated with CIMZIA - the only PEGylated anti-TNF-alpha (Tumor Necrosis Factor alpha) - remained in long-term remission without dose escalation up to 3.5 years. In a separate analysis, CIMZIA significantly improved...

2009-10-21 08:00:00

ATLANTA, Oct. 21 /PRNewswire/ -- UCB today announced the 31 recipients of the fourth annual UCB Crohn's Scholarship, awarded to outstanding students of all ages who are living beyond the boundaries of Crohn's disease. To date, the company has granted more than $1 million to individuals pursuing their educational dreams. The 2009 winners are a stellar group of men and women who excel in school, sports, volunteerism and activism despite living with Crohn's disease, a debilitating, chronic...

2009-10-09 23:01:00

PHILADELPHIA, October 10 /PRNewswire-FirstCall/ -- For U.S. Media Only - U.S. women living with rheumatoid arthritis demand more 'good days' - 68 percent of women living with rheumatoid arthritis look for new pain relief therapies to help them cope - Almost 60 percent of women in the U.S. living with rheumatoid arthritis find intimate relations painful - Rheumatoid arthritis played a role in 25 percent of divorces amongst women with the disease A new survey...

2009-09-02 05:00:00

SANTA MONICA, Calif., Sept. 2 /PRNewswire/ -- MTV has tapped hip-hop's newest challenger, Wale and the legendary go-go band UCB as the official house band for the 2009 VMAs, providing the night's soundtrack for the hottest music awards show this year. Not only will Wale perform his new hit single "World Tour," but he will also collaborate with artists including The All-American Rejects, Pitbull and 3OH!3 while putting his own unique spin on some of the biggest songs of the year. "This...

2009-08-26 11:51:00

EL PASO, Texas, Aug. 26 /PRNewswire-FirstCall/ -- Helen of Troy Limited (Nasdaq: HELE) designer, developer and worldwide marketer of brand-name personal care and household consumer products, today announced that the Company's OXO Housewares Division, along with its design partners, Smart Design and the Brussels-based biopharmaceutical company UCB, have been awarded the Red Dot Communication Design award for packaging used for the rheumatoid arthritis drug Cimzia. Gerald J. Rubin, Chairman,...

2009-06-24 15:30:00

Preliminary top-line results of second Phase III study show highly significant decreases in pain and fatigue and improved daily function in fibromyalgia patients and confirm results from the first Phase III study PALO ALTO, Calif., and BRUSSELS, June 24 /PRNewswire-FirstCall/ -- press release, regulated information -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) and UCB (Euronext Brussels: UCB) announced today positive preliminary top-line results from the second of two Phase III clinical...

2009-06-24 09:29:00

ALLEGAN, Mich., June 24 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that its partner Synthon Pharmaceuticals, Inc. has filed an Abbreviated New Drug Application (ANDA) for Levocetirizine solution 2.5mg/5ml, a generic version of Xyzal(R) solution 2.5mg/5ml. Under terms of an exclusive agreement between the companies, Perrigo has sales and marketing rights in Synthon's Levocetirizine products. The Company believes that Synthon is the first to file an ANDA...

2009-06-09 08:00:00

Overall Market Will Increase by a Modest $300 Million From 2008 to 2018, According to a New Report from Decision Resources WALTHAM, Mass., June 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the Parkinson's disease drug market, fueled by the launch of several new therapies through 2018, will be offset by generic erosion of key currently-available agents. As a result, sales of...

2009-06-01 08:07:00

CHICAGO, June 1 /PRNewswire/ -- UCB, Inc. and the Crohn's Disease Working Group (CDWG) today announced the four recipients of the 2009 Research Awards in Inflammatory Bowel Disease (IBD) for Gastroenterology (GI) Fellows, who each will receive a one-year research grant for their original clinical or basic research, totaling $175,000 for all four grants. The recipients were selected by the CDWG Steering Committee and the awards were funded by a grant from UCB. A reception honoring the...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.